131 related articles for article (PubMed ID: 12194721)
21. Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma.
Satwani P; Jin Z; Martin PL; Bhatia M; Garvin JH; George D; Chaudhury S; Talano J; Morris E; Harrison L; Sosna J; Peterson M; Militano O; Foley S; Kurtzberg J; Cairo MS
Leukemia; 2015 Feb; 29(2):448-55. PubMed ID: 24938649
[TBL] [Abstract][Full Text] [Related]
22. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P
Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324
[TBL] [Abstract][Full Text] [Related]
23. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial.
Stiff PJ; Dahlberg S; Forman SJ; McCall AR; Horning SJ; Nademanee AP; Blume KG; LeBlanc M; Fisher RI
J Clin Oncol; 1998 Jan; 16(1):48-55. PubMed ID: 9440722
[TBL] [Abstract][Full Text] [Related]
24. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
[TBL] [Abstract][Full Text] [Related]
25. [Salvage therapy in relapsed or refractory malignant lymphoma].
Kashimura T; Murohashi I
Nihon Rinsho; 2000 Mar; 58(3):699-703. PubMed ID: 10741149
[TBL] [Abstract][Full Text] [Related]
26. Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age.
Stamatoullas A; Fruchart C; Khalfallah S; Buchonnet G; Contentin N; Bastit D; Tilly H
Bone Marrow Transplant; 1997 Jan; 19(1):31-5. PubMed ID: 9012928
[TBL] [Abstract][Full Text] [Related]
27. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.
Phillips GL; Meisenberg BR; Reece DE; Adams VR; Badros AZ; Brunner JL; Fenton RG; Filicko J; Grosso DL; Hale GA; Howard DS; Johnson VP; Kniska A; Marshall KW; Mookerjee B; Nath R; Rapoport AP; Sarkodee-Adoo C; Takebe N; Vesole DH; Wagner JL; Flomenberg N
Bone Marrow Transplant; 2004 Apr; 33(8):781-7. PubMed ID: 14767498
[TBL] [Abstract][Full Text] [Related]
28. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy.
Molina A; Krishnan AY; Nademanee A; Zabner R; Sniecinski I; Zaia J; Forman SJ
Cancer; 2000 Aug; 89(3):680-9. PubMed ID: 10931469
[TBL] [Abstract][Full Text] [Related]
29. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
Bierman PJ; Sweetenham JW; Loberiza FR; Taghipour G; Lazarus HM; Rizzo JD; Schmitz N; van Besien K; Vose JM; Horowitz M; Goldstone A;
J Clin Oncol; 2003 Oct; 21(20):3744-53. PubMed ID: 12963703
[TBL] [Abstract][Full Text] [Related]
30. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS
Biol Blood Marrow Transplant; 2011 Jul; 17(7):987-94. PubMed ID: 20965266
[TBL] [Abstract][Full Text] [Related]
31. Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients.
Ruiz-Soto R; Sergent G; Gisselbrecht C; Larghero J; Ertault M; Hennequin C; Manson J; de Kerviler E; Briere J; Mounier N
Cancer; 2005 Dec; 104(12):2735-42. PubMed ID: 16284986
[TBL] [Abstract][Full Text] [Related]
32. Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Osumi T; Mori T; Fujita N; Saito AM; Nakazawa A; Tsurusawa M; Kobayashi R
Pediatr Blood Cancer; 2016 Oct; 63(10):1794-9. PubMed ID: 27314926
[TBL] [Abstract][Full Text] [Related]
33. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma.
Stockerl-Goldstein KE; Horning SJ; Negrin RS; Chao NJ; Hu WW; Long GD; Hoppe RT; Amylon MD; Brown BW; Wong RM; Blume KG
Biol Blood Marrow Transplant; 1996 May; 2(2):76-85. PubMed ID: 9118302
[TBL] [Abstract][Full Text] [Related]
34. [Outcome of haploidentical hematopoietic stem cell transplantation for non-Hodgkin lymphoma].
Xu T; Chen J; Jin ZM; Miao M; Fu CC; Qiu HY; Tang XW; Han Y; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2016 Aug; 37(8):656-60. PubMed ID: 27587245
[TBL] [Abstract][Full Text] [Related]
35. [Recent progress in the treatment of malignant lymphoma].
Ogura M
Gan To Kagaku Ryoho; 2001 Sep; 28(9):1213-35. PubMed ID: 11579632
[TBL] [Abstract][Full Text] [Related]
36. Hematopoietic stem cell transplantation for non-Hodgkin lymphoma.
Bhatt VR; Vose JM
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1073-95. PubMed ID: 25459180
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
[TBL] [Abstract][Full Text] [Related]
38. Salvage therapy with ProMACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first-line CHOP.
Verdonck LF; Dekker AW; de Gast GC; van Kempen ML; Lokhorst HM; Nieuwenhuis HK
J Clin Oncol; 1992 Dec; 10(12):1949-54. PubMed ID: 1453209
[TBL] [Abstract][Full Text] [Related]
39. Hematopoietic stem cell transplantation in the new millennium: report from City of Hope National Medical Center.
Molina A; Popplewell L; Kashyap A; Nademanee A
Clin Transpl; 2000; ():317-42. PubMed ID: 11512326
[TBL] [Abstract][Full Text] [Related]
40. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma.
Kewalramani T; Nimer SD; Zelenetz AD; Malhotra S; Qin J; Yahalom J; Moskowitz CH
Bone Marrow Transplant; 2003 Oct; 32(7):673-9. PubMed ID: 13130314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
